Advertisement

The Tetracycline Responsive System

  • Nasim Yousaf
  • David GouldEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1651)

Abstract

Constitutive gene expression is not always the appropriate expression system because the unphysiological levels of expressed protein could be detrimental in studies examining biological roles of proteins, or continued expression may be unnecessary after therapeutic effects have been achieved in gene therapy. We have utilized pharmacologically regulated gene expression systems to achieve fine control of gene expression levels which facilitate research in basic biology and translates to use in experimental gene therapy studies. In this chapter, we outline the application of a tightly controlled tetracycline responsive gene expression system.

Key words

Gene expression Tetracycline-inducible system Cell transfection Western blotting Pharmacological Luciferase assay 

Notes

Acknowledgments

This work was supported by ARUK project grant 21210 “Sustained and Controllable Local Delivery of Anti-inflammatory Therapeutics with Nanoengineered Microcapsules.”

References

  1. 1.
    No D, Yao TP, Evans RM (1996) Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A 93:3346–3351Google Scholar
  2. 2.
    Nishijima H, Yasunari T, Nakayama T, Adachi N, Shibahara K (2009) Improved applications of the tetracycline-regulated gene depletion system. Biosci Trends 3:161–167PubMedGoogle Scholar
  3. 3.
    Karzenowski D, Potter DW, Padidam M (2005) Inducible control of transgene expression with ecdysone receptor: gene switches with high sensitivity, robust expression, and reduced size. Biotechniques 39:191–200CrossRefGoogle Scholar
  4. 4.
    Lee YB, Glover CP, Cosgrave AS, Bienemann A, Uney JB (2005) Optimizing regulatable gene expression using adenoviral vectors. Exp Physiol 90:33–37CrossRefGoogle Scholar
  5. 5.
    Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline- responsive promoters. Proc Natl Acad Sci U S A 89:5547–5551Google Scholar
  6. 6.
    Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766–1769CrossRefGoogle Scholar
  7. 7.
    Rubinchik S, Woraratanadharm J, Yu H, Dong JY (2005) New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo. Gene Ther 12:504–511CrossRefGoogle Scholar
  8. 8.
    Howe JR, Skryabin BV, Belcher SM, Zerillo CA, Schmauss C (1995) The responsiveness of a tetracycline-sensitive expression system differs in different cell lines. J Biol Chem 270:14,168–14,174CrossRefGoogle Scholar
  9. 9.
    Forster K, Helbl V, Lederer T, Urlinger S, Wittenburg N, Hillen W (1999) Tetracycline-inducible expression systems with reduced basal activity in mammalian cells. Nucleic Acids Res 27:708–710Google Scholar
  10. 10.
    Collins T, Stone JR, Williams AJ (2001) All in the family: the BTB/POZ, KRAB, and SCAN domains. Mol Cell Biol 21:3609–3615CrossRefGoogle Scholar
  11. 11.
    Yousaf N, Gould DJ, Aganna E, Hammond L, Mirakian RM, Turner MD, Hitman GA, McDermott MF, Chernajovsky Y (2005) Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-kappaB activation. Arthritis Rheum 52:2906–2916CrossRefGoogle Scholar
  12. 12.
    Gould DJ, Yousaf N, Fatah R, Subang MC, Chernajovsky Y (2007) Gene therapy with an improved doxycycline regulated plasmid encoding a TNFalpha inhibitor in experimental arthritis. Arthritis Res Ther 9:R7CrossRefGoogle Scholar
  13. 13.
    Luo D, Gould DJ, Sukhorukov GB (2016) Local and sustained activity of doxycycline delivered with layer-by-layer microcapsules. Biomacromolecules 17:1466–1476CrossRefGoogle Scholar
  14. 14.
    Rang A, Will H (2000) The tetracycline-responsive promoter contains functional interferon-inducible response elements. Nucleic Acids Res 28:1120–1125CrossRefGoogle Scholar
  15. 15.
    Gould DJ, Chernajovsky Y (2004) Endogenous GATA factors bind the core sequence of the tetO and influence gene regulation with the tetracycline system. Mol Ther 10:127–138CrossRefGoogle Scholar
  16. 16.
    Deuschle U, Meyer WK, Thiesen HJ (1995) Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 15:1907–1914CrossRefGoogle Scholar
  17. 17.
    Subang MC, Fatah R, Bright C, Blanco P, Berenstein M, Wu Y, Podhajcer OL, Winyard PG, Chernajovsky Y, Gould D (2012) A novel hybrid promoter responsive to pathophysiological and pharmacological regulation. J Mol Med (Berl) 90:401–411CrossRefGoogle Scholar
  18. 18.
    Sturtz FG, Cioffi L, Wittmer S, Sonk MJ, Shafer A, Li Y, Leeper NJ, Smith-Gbur J, Shulok J, Platika D (1998) Tetracycline-regulatable expression vectors tightly regulate in vitro gene expression of secreted proteins. Gene 221:279–285CrossRefGoogle Scholar
  19. 19.
    Gossen M, Bujard H (1993) Anhydrotetracycline, a novel effector for tetracycline controlled gene expression systems in eukaryotic cells. Nucleic Acids Res 21:4411–4412CrossRefGoogle Scholar
  20. 20.
    Castro MM, Kandasamy AD, Youssef N, Schulz R (2011) Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res 64:551–560CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Bone and Joint Research Unit, William Harvey Research InstituteQueen Mary University of LondonLondonUK
  2. 2.Department of Biochemical Pharmacology, William Harvey Research InstituteQueen Mary University of LondonLondonUK

Personalised recommendations